Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2012

Open Access 01-12-2012 | Review

MicroRNA manipulation in colorectal cancer cells: from laboratory to clinical application

Authors: Muhammad Imran Aslam, Maleene Patel, Baljit Singh, John Stuart Jameson, James Howard Pringle

Published in: Journal of Translational Medicine | Issue 1/2012

Login to get access

Abstract

The development of Colorectal Cancer (CRC) follows a sequential progression from adenoma to the carcinoma. Therefore, opportunities exist to interfere with the natural course of disease development and progression. Dysregulation of microRNAs (miRNAs) in cancer cells indirectly results in higher levels of messenger RNA (mRNA) specific to tumour promoter genes or tumour suppressor genes. This narrative review aims to provide a comprehensive review of the literature about the manipulation of oncogenic or tumour suppressor miRNAs in colorectal cancer cells for the purpose of development of anticancer therapies. A literature search identified studies describing manipulation of miRNAs in colorectal cancer cells in vivo and in vitro. Studies were also included to provide an update on the role of miRNAs in CRC development, progression and diagnosis. Strategy based on restoration of silenced miRNAs or inhibition of over expressed miRNAs has opened a new area of research in cancer therapy. In this review article different techniques for miRNA manipulation are reviewed and their utility for colorectal cancer therapy has been discussed in detail. Restoration of normal equilibrium for cancer related miRNAs can result in inhibition of tumour growth, apoptosis, blocking of invasion, angiogenesis and metastasis. Furthermore, drug resistant cancer cells can be turned into drug sensitive cells on alteration of specific miRNAs in cancer cells. MiRNA modulation in cancer cells holds great potential to replace current anticancer therapies. However, further work is needed on tissue specific delivery systems and strategies to avoid side effects.
Appendix
Available only for authorised users
Literature
1.
2.
Coleman M, Estève J, Damiecki P, Arslan A, Renard H: Trends in Cancer Incidence and Mortality, IARC Scientific Publications. 1993, IARC, Lyon
3.
Ferlay J, Parkin DM, Steliarova-Foucher E: Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010, 46 (4): 765-781. 10.1016/j.ejca.2009.12.014.CrossRefPubMed
4.
Marchand L: Combined influence of genetic and dietary factors on colorectal cancer incidence in Japanese Americans. J Natl Cancer Inst Monogr. 1999, 26: 101-105.CrossRefPubMed
5.
6.
Bray F, Atkin W: International cancer patterns in men: geographical and temporal variations in cancer risk and the role of gender. JMHG. 2004, 1 (1): 38-46.
7.
Vogelstein B, Fearon ER, Hamilton SR: Genetic alterations during colorectal- tumor development. N Engl J Med. 1988, 319 (9): 525-532. 10.1056/NEJM198809013190901.CrossRefPubMed
8.
Lee RC, Feinbaum RL, The AV: The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993, 75 (5): 843-854. 10.1016/0092-8674(93)90529-Y.CrossRefPubMed
9.
Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004, 116 (2): 281-297. 10.1016/S0092-8674(04)00045-5.CrossRefPubMed
10.
11.
Lee Y, Ahn C, Han J: The nuclear RNase III Drosha initiates microRNA processing. Nature. 2003, 425: 415-419. 10.1038/nature01957.CrossRefPubMed
12.
Bohnsack MT, Czaplinski K, Gorlich D: Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs. RNA. 2004, 10: 185-191. 10.1261/rna.5167604.CrossRefPubMedPubMedCentral
13.
Thimmaiah P: TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. Nature. 2005, 436: 740-744. 10.1038/nature03868.CrossRef
14.
Hammond S, Bernstein E, Beach D: An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature. 2000, 404: 293-296. 10.1038/35005107.CrossRefPubMed
15.
16.
Ørom UA, Nielsen FN, Lund AH: MicroRNA-10a binds the 5′UTR of ribosomal protein mRNAs and enhances their translation. Mol Cell. 2008, 4: 460-471.CrossRef
17.
Eiring A: miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. Cell. 2010, 140: 652-665. 10.1016/j.cell.2010.01.007.CrossRefPubMedPubMedCentral
18.
Khraiwesh B: Transcriptional control of gene expression by microRNAs. Cell. 2010, 140: 112-122.CrossRef
19.
Esquela-Kerscher A, Slack FJ: Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006, 6 (4): 259-269. 10.1038/nrc1840.CrossRefPubMed
20.
Huang Q, Gumireddy K, Schrier M: The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol. 2008, 10 (2): 202-210. 10.1038/ncb1681.CrossRefPubMed
21.
Zhang BG, Li JF, Yu BQ: microRNA-21 promotes tumor proliferation and invasion in gastric cancer by targeting PTEN. Oncol Rep. 2012, 27 (4): 1019-1026.PubMedPubMedCentral
22.
Lee DY, Deng Z, Wang CH: MicroRNA-378 promotes cell survival, tumor growth, and angiogenesis by targeting SuFu and Fus-1 expression. Proc Natl Acad Sci U S A. 2007, 104 (51): 20350-20355. 10.1073/pnas.0706901104.CrossRefPubMedPubMedCentral
23.
Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell. 1990, 61: 759-767. 10.1016/0092-8674(90)90186-I.CrossRefPubMed
24.
Salby O, Svoboda M, Michalek J: MicroRNAs in colorectal cancer: translation of molecular biology into clinical application. Mol Cancer. 2009, 14: 8-102.
25.
Segditsas S, Tomlinson I: Colorectal cancer and genetic alterations in the Wnt pathway. Oncogene. 2006, 25 (57): 7531-7537. 10.1038/sj.onc.1210059.CrossRefPubMed
26.
Nagel R, le Sage C, Diosdado B, Waal M: Oude Vrielink JA, Bolijn A, Meijer GA, Agami R: Regulation of the adenomatous polyposis coli gene by the miR-135 family in colorectal cancer. Cancer Res. 2008, 68: 5795-5802. 10.1158/0008-5472.CAN-08-0951.CrossRefPubMed
27.
Akao Y, Nakagawa Y, Naoe T: let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. Biol Pharm Bull. 2006, 29: 903-906. 10.1248/bpb.29.903.CrossRefPubMed
28.
Chen X, Guo X, Zhang H, Xiang Y, Chen J, Yin Y, Cai X, Wang K, Wang G, Ba Y, Zhu L, Wang J, Yang R, Zhang Y, Ren Z, Zen K, Zhang J, Zhang CY: Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene. 2009, 28: 1385-1392. 10.1038/onc.2008.474.CrossRefPubMed
29.
Tsang WP, Kwok TT: The miR-18a* microRNA functions as a potential tumor suppressor by targeting on K-Ras. Carcinogenesis. 2009, 30: 953-959. 10.1093/carcin/bgp094.CrossRefPubMed
30.
31.
Guo C, Sah JF, Beard L, Willson JK, Markowitz SD, Guda K: The noncoding RNA, miR-126, suppresses the growth of neoplastic cells by targeting phosphatidylinositol 3-kinase signaling and is frequently lost in colon cancers. Genes Chromosomes Cancer. 2008, 47: 939-946. 10.1002/gcc.20596.CrossRefPubMedPubMedCentral
32.
Chang TC, Wentzel EA, Kent OA: Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell. 2007, 26 (5): 745-752. 10.1016/j.molcel.2007.05.010.CrossRefPubMedPubMedCentral
33.
Diosdado B, van de Wiel MA, Terhaar Sive Droste JS: MiR-17-92 cluster is associated with 13q gain and c-myc expression during colorectal adenoma to adenocarcinoma progression. Br J Cancer. 2009, 101 (4): 707-714. 10.1038/sj.bjc.6605037.CrossRefPubMedPubMedCentral
34.
Spring KJ, Zhao ZZ, Karamatic R: High prevalence of sessile serrated adenomas with BRAF mutations: a prospective study of patients undergoing colonoscopy. Gastroenterology. 2006, 131 (5): 1400-1407. 10.1053/j.gastro.2006.08.038.CrossRefPubMed
35.
Casey G, Lindor NM, Papadopoulos N: Colon Cancer Family Registry. Conversion analysis for mutation detection in MLH1 and MSH2 in patients with colorectal cancer. JAMA. 2005, 293 (7): 799-809. 10.1001/jama.293.7.799.CrossRefPubMedPubMedCentral
36.
Michael MZ, O' Connor SM, van Holst Pellekaan NG: Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res. 2003, 12 (1): 882-891.
37.
Volinia S, Calin GA, Liu CG: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006, 103 (7): 2257-2261. 10.1073/pnas.0510565103.CrossRefPubMedPubMedCentral
38.
Bandrés E, Cubedo E, Agirre X: Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol Cancer. 2006, 5: 29-CrossRefPubMedPubMedCentral
39.
Akao Y, Nakagawa Y, Naoe T: MicroRNAs 143 and 145 are possible common onco-microRNAs in human cancers. Oncol Rep. 2006, 16 (4): 845-850.PubMed
40.
Nakajima G, Hayashi K, Xi Y: Non-coding MicroRNAs hsa-let-7 g and hsa-miR-181b are Associated with hemoresponse to S-1 in Colon Cancer. Cancer Genomics Proteomics. 2006, 3 (5): 317-324.PubMedPubMedCentral
41.
Lanza G, Ferracin M, Gafà R: mRNA/microRNA gene expression profile in microsatellite unstable colorectal cancer. Mol Cancer. 2007, 6: 54-10.1186/1476-4598-6-54.CrossRefPubMedPubMedCentral
42.
Rossi L, Bonmassar E, Faraoni I: Modification of miR gene expression pattern in human colon cancer cells following exposure to 5-fluorouracil in vitro. Pharmacol Res. 2007, 56 (3): 248-253. 10.1016/j.phrs.2007.07.001.CrossRefPubMed
43.
Monzo M, Navarro A, Bandres E: Overlapping expression of microRNAs in human embryonic colon and colorectal cancer. Cell Res. 2008, 18 (8): 823-833. 10.1038/cr.2008.81.CrossRefPubMed
44.
Schepeler T, Reinert JT, Ostenfeld MS: Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Res. 2008, 68 (15): 6416-6424. 10.1158/0008-5472.CAN-07-6110.CrossRefPubMed
45.
Schetter AJ, Leung SY, Sohn JJ: MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA. 2008, 299 (4): 425-436. 10.1001/jama.299.4.425.CrossRefPubMedPubMedCentral
46.
Arndt GM, Dossey L, Cullen LM: Characterization of global microRNA expression reveals oncogenic potential of miR-145 in metastatic colorectal cancer. BMC Cancer. 2009, 9: 374-10.1186/1471-2407-9-374.CrossRefPubMedPubMedCentral
47.
Slattery ML, Wolff E, Hoffman MD: MicroRNAs and colon and rectal cancer: differential expression by tumor location and subtype. Genes Chromosomes Cancer. 2011, 50 (3): 196-206. 10.1002/gcc.20844.CrossRefPubMedPubMedCentral
48.
Xi Y, Formentini A, Chien M: Prognostic Values of microRNAs in Colorectal Cancer. Biomark Insights. 2006, 2: 113-121.PubMed
49.
Slaby O, Svoboda M, Fabian P: Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology. 2007, 72 (5–6): 397-402.PubMed
50.
Chen X, Ba Y, Ma L: Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008, 18 (10): 997-1006. 10.1038/cr.2008.282.CrossRefPubMed
51.
Pu XX, Huang GL, Guo HQ: Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression. J Gastroenterol Hepatol. 2010, 25 (10): 1674-1680. 10.1111/j.1440-1746.2010.06417.x.CrossRefPubMed
52.
Cheng H, Zhang L, Cogdell DE: Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS One. 2011, 6 (3): e17745-10.1371/journal.pone.0017745.CrossRefPubMedPubMedCentral
53.
Ng EK, Chong WW, Jin H: Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut. 2009, 58 (10): 1375-1381. 10.1136/gut.2008.167817.CrossRefPubMed
54.
Huang Z, Huang D, Ni S: Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer. 2010, 127 (1): 118-126. 10.1002/ijc.25007.CrossRefPubMed
55.
Taylor DD, Gercel-Taylor C: MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol. 2008, 110 (1): 13-21. 10.1016/j.ygyno.2008.04.033.CrossRefPubMed
56.
Dias N, Stein CA: Antisense oligonucleotides: basic concepts and mechanisms. Mol Cancer Ther. 2002, 1 (5): 347-355.PubMed
57.
Weiler J, Hunziker J, Hall J: Anti-miRNA oligonucleotides (AMOs): ammunition to target miRNAs implicated in human disease?. Gene Ther. 2006, 13 (6): 496-502. 10.1038/sj.gt.3302654.CrossRefPubMed
58.
59.
60.
Cimmino A, Calin GA, Fabbri M: miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A. 2005, 102 (39): 13944-13949. 10.1073/pnas.0506654102.CrossRefPubMedPubMedCentral
61.
Chai H, Liu M, Tian R: miR-20a targets BNIP2 and contributes chemotherapeutic resistance in colorectal adenocarcinoma SW480 and SW620 cell lines. Acta Biochim Biophys Sin (Shanghai). 2011, 43 (3): 217-225. 10.1093/abbs/gmq125.CrossRef
62.
Asangani IA, Rasheed SA, Nikolova DA: MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene. 2008, 27 (15): 2128-2136. 10.1038/sj.onc.1210856.CrossRefPubMed
63.
Wang CJ, Stratmann J, Zhou ZG: Suppression of microRNA-31 increases sensitivity to 5-FU at an early stage, and affects cell migration and invasion in HCT-116 colon cancer cells. BMC Cancer. 2010, 10: 616-10.1186/1471-2407-10-616.CrossRefPubMedPubMedCentral
64.
Huang Z, Huang S, Wang Q: MicroRNA-95 promotes cell proliferation and targets sorting Nexin 1 in human colorectal carcinoma. Cancer Res. 2011, 71 (7): 2582-2589. 10.1158/0008-5472.CAN-10-3032.CrossRefPubMed
65.
Tsang WP, Ng EK, Ng SS: Oncofetal H19-derived miR-675 regulates tumor suppressor RB in human colorectal cancer. Carcinogenesis. 2010, 31 (3): 350-358. 10.1093/carcin/bgp181.CrossRefPubMed
66.
Veedu RN, Wengel J: Locked nucleic acids: promising nucleic acid analogs for therapeutic applications. Chem Biodivers. 2010, 7 (3): 536-542. 10.1002/cbdv.200900343.CrossRefPubMed
67.
Valeri N, Gasparini P, Braconi C: MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). Proc Natl Acad Sci U S A. 2010, 107 (49): 21098-21103. 10.1073/pnas.1015541107.CrossRefPubMedPubMedCentral
68.
Kauppinen S, Vester B, Wengel J: Locked nucleic acid: high-affinity targeting of complementary RNA for RNomics. Handb Exp Pharmacol. 2006, 173: 405-422. 10.1007/3-540-27262-3_21.CrossRefPubMed
69.
Ebert MS, Neilson JR, Sharp PA: MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods. 2007, 4 (9): 721-726. 10.1038/nmeth1079.CrossRefPubMed
70.
Xiao J, Yang B, Lin H: Novel approaches for gene-specific interference via manipulating actions of microRNAs: examination on the pacemaker channel genes HCN2 and HCN4. J Cell Physiol. 2007, 212 (2): 285-292. 10.1002/jcp.21062.CrossRefPubMed
71.
Choi WY, Giraldez AJ, Schier AF: Target protectors reveal dampening and balancing of Nodal agonist and antagonist by miR-430. Science. 2007, 318 (5848): 271-274. 10.1126/science.1147535.CrossRefPubMed
72.
Gumireddy K, Young DD, Xiong X: Small-molecule inhibitors of microrna miR-21 function. Angew Chem Int Ed Engl. 2008, 47 (39): 7482-7484. 10.1002/anie.200801555.CrossRefPubMedPubMedCentral
73.
Soussi T, Béroud C: Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer. 2001, 1: 233-240. 10.1038/35106009.CrossRefPubMed
74.
Soussi T, Asselain B, Hamroun D: Meta-analysis of the p53 mutation database for mutant p53 biological activity reveals a methodologic bias in mutation detection. Clin Cancer Res. 2006, 12 (1): 62-69. 10.1158/1078-0432.CCR-05-0413.CrossRefPubMed
75.
Akao Y, Noguchi S, Iio A: Dysregulation of microRNA-34a expression causes drug-resistance to 5-FU in human colon cancer DLD-1 cells. Cancer Lett. 2011, 300 (2): 197-204. 10.1016/j.canlet.2010.10.006.CrossRefPubMed
76.
Mudduluru G, Ceppi P, Kumarswamy R: Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer. Oncogene. 2011, 30 (25): 2888-99. 10.1038/onc.2011.13.CrossRefPubMed
77.
Hermeking H: The miR-34 family in cancer and apoptosis. Cell Death Differ. 2010, 17: 193-199. 10.1038/cdd.2009.56.CrossRefPubMed
78.
Cole KA, Attiyeh EF, Mosse YP: A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene. Mol Cancer Res. 2008, 6: 735-742. 10.1158/1541-7786.MCR-07-2102.CrossRefPubMedPubMedCentral
79.
Ng EK, Tsang WP, Ng SS: MicroRNA-143 targets DNA methyltransferases 3A in colorectal cancer. Br J Cancer. 2009, 101 (4): 699-706. 10.1038/sj.bjc.6605195.CrossRefPubMedPubMedCentral
80.
Nakagawa Y, Iinuma M, Naoe T: Characterized mechanism of alpha-mangostin-induced cell death: caspase-independent apoptosis with release of endonuclease-G from mitochondria and increased miR-143 expression in human colorectal cancer DLD-1 cells. Bioorg Med Chem. 2007, 15 (16): 5620-5628. 10.1016/j.bmc.2007.04.071.CrossRefPubMed
81.
Hu G, Chen D, Li X: miR-133b regulates the MET proto-oncogene and inhibits the growth of colorectal cancer cells in vitro and in vivo. Cancer Biol Ther. 2010, 10 (2): 190-197. 10.4161/cbt.10.2.12186.CrossRefPubMed
82.
Li LN, Zhang HD, Zhi R: Down-regulation of some miRNAs by degrading their precursors contributes to anti-cancer effect of mistletoe lectin-I. Br J Pharmacol. 2011, 162 (2): 349-364. 10.1111/j.1476-5381.2010.01042.x.CrossRefPubMedPubMedCentral
83.
Liu M, Lang N, Qiu M: miR-137 targets Cdc42 expression, induces cell cycle G1 arrest and inhibits invasion in colorectal cancer cells. Int J Cancer. 2011, 128 (6): 1269-1279. 10.1002/ijc.25452.CrossRefPubMed
84.
Zhang J, Guo H, Zhang H: Putative tumor suppressor miR-145 inhibits colon cancer cell growth by targeting oncogene Friend leukemia virus integration 1 gene. Cancer. 2011, 117 (1): 86-95. 10.1002/cncr.25522.CrossRefPubMedPubMedCentral
85.
Shi B, Sepp-Lorenzino L, Prisco M: Micro RNA 145 targets the insulin receptor substrate-1 and inhibits the growth of colon cancer cells. J Biol Chem. 2007, 282 (45): 32582-32590. 10.1074/jbc.M702806200.CrossRefPubMed
86.
Liu M, Lang N, Chen X: miR-185 targets RhoA and Cdc42 expression and inhibits the proliferation potential of human colorectal cells. Cancer Lett. 2011, 301 (2): 151-160. 10.1016/j.canlet.2010.11.009.CrossRefPubMed
87.
Boni V, Bitarte N, Cristobal I: miR-192/miR-215 influence 5-fluorouracil resistance through cell cycle-mediated mechanisms complementary to its post-transcriptional thymidilate synthase regulation. Mol Cancer Ther. 2010, 9 (8): 2265-2275. 10.1158/1535-7163.MCT-10-0061.CrossRefPubMed
88.
Liu L, Chen L, Xu Y: microRNA-195 promotes apoptosis and suppresses tumorigenicity of human colorectal cancer cells. Biochem Biophys Res Commun. 2010, 400 (2): 236-240. 10.1016/j.bbrc.2010.08.046.CrossRefPubMed
89.
Schimanski CC, Frerichs K, Rahman F: High miR-196a levels promote the oncogenic phenotype of colorectal cancer cells. World J Gastroenterol. 2009, 15 (17): 2089-2096. 10.3748/wjg.15.2089.CrossRefPubMedPubMedCentral
90.
Nakano H, Miyazawa T, Kinoshita K: Functional screening identifies a microRNA, miR-491 that induces apoptosis by targeting Bcl-X(L) in colorectal cancer cells. Int J Cancer. 2010, 127 (5): 1072-1080.CrossRefPubMed
91.
Kumar MS, Lu J, Mercer KL: Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet. 2007, 39 (5): 673-677. 10.1038/ng2003.CrossRefPubMed
92.
Merritt WM, Lin YG, Han LY: Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med. 2008, 359 (25): 2641-2650. 10.1056/NEJMoa0803785.CrossRefPubMedPubMedCentral
93.
Karube Y, Tanaka H, Osada H: Reduced expression of Dicer associated with poor prognosis in lung cancer patients. Cancer Sci. 2005, 96 (2): 111-115. 10.1111/j.1349-7006.2005.00015.x.CrossRefPubMed
94.
Chiosea S, Jelezcova E, Chandran U: Overexpression of Dicer in precursor lesions of lung adenocarcinoma. Cancer Res. 2007, 67 (5): 2345-2350. 10.1158/0008-5472.CAN-06-3533.CrossRefPubMed
95.
Gupta PB, Chaffer CL, Weinberg RA: Cancer stem cells: mirage or reality?. Nat Med. 2009, 15 (9): 1010-1012. 10.1038/nm0909-1010.CrossRefPubMed
96.
Matsui W, Wang Q, Barber JP: Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res. 2008, 68 (1): 190-197. 10.1158/0008-5472.CAN-07-3096.CrossRefPubMedPubMedCentral
97.
Visvader JE, Lindeman GJ: Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008, 8 (10): 755-768. 10.1038/nrc2499.CrossRefPubMed
98.
99.
Zhu R, Yang Y, Tian Y: Ascl2 knockdown results in tumor growth arrest by miRNA-302b-related inhibition of colon cancer progenitor cells. PLoS One. 2012, 7 (2): e32170-10.1371/journal.pone.0032170.CrossRefPubMedPubMedCentral
100.
Wang Y, Medvid R, Melton C: DGCR8 is essential for microRNA biogenesis and silencing of embryonic stem cell self renewal. Nat Genet. 2007, 39: 380-385. 10.1038/ng1969.CrossRefPubMedPubMedCentral
101.
Kanellopoulou C, Muljo SA, Kung AL: Dicer-deficient mouse embryonic stem cells are defective in differentiation and centromeric silencing. Genes. 2005, 19 (4): 489-501. 10.1101/gad.1248505.CrossRef
102.
Calabrese JM, Seila AC, Yeo GW: RNA sequence analysis defines Dicer’s role in mouse embryonic stem cells. Proc Natl Acad Sci USA. 2004, 104 (46): 18097-18102.CrossRef
Metadata
Title
MicroRNA manipulation in colorectal cancer cells: from laboratory to clinical application
Authors
Muhammad Imran Aslam
Maleene Patel
Baljit Singh
John Stuart Jameson
James Howard Pringle
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2012
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-10-128

Other articles of this Issue 1/2012

Journal of Translational Medicine 1/2012 Go to the issue

Review

Cancer classification using the Immunoscore: a worldwide task force

Research

Continuing Exposure to Low-Dose Nonylphenol Aggravates Adenine-Induced Chronic Renal Dysfunction and Role of Rosuvastatin Therapy

Research

Alzheimer's disease biomarker discovery using in silico literature mining and clinical validation

Research

Chemokine CXCL12 activates dual CXCR4 and CXCR7-mediated signaling pathways in pancreatic cancer cells

Research

Five novel glucose-6-phosphate dehydrogenase deficiency haplotypes correlating with disease severity

Research

Biomarkers on melanoma patient T Cells associated with ipilimumab treatment
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits